Company / SG&A Expense
LEXICON PHARMACEUTICALS, INC. SG&A Expense History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$114.0M
FY2025
5-year range
$32.3M / $114.0M
FY2021-FY2025
Trend
+137.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $17M in FY2014 to $114M in FY2025.
Based on SEC 10-K filings.
$114M in FY2025 with a 10-year CAGR of +20.9%.
Increased from $32M to $114M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +20.9%
Key checks
Key Insights
- In FY2025, sg&a expense increased 137.1% year-over-year.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -1.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.0M | +137.1% |
| FY2024 | $48.1M | +48.7% |
| FY2023 | $32.3M | -31.5% |
| FY2019 | $47.2M | +9.4% |
| FY2018 | $43.2M | +81.1% |
| FY2017 | $23.8M | +22.8% |
| FY2016 | $19.4M | +13.4% |
| FY2015 | $17.1M | +0.5% |
| FY2014 | $17.0M | -1.8% |
| FY2013 | $17.4M | -10.5% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026